Repatha, the sole PCSK9 inhibitor, has demonstrated a reduction in the risk of all-cause mortality, along with cardiovascular events, in high-risk primary prevention patients during a Phase 3 trial. Global real-world analyses have highlighted ongoing deficiencies in lipid management, indicating significant gaps in care for numerous high-risk individuals.
